Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1716
    +0.0022 (+0.19%)
     
  • GBP/USD

    1.2625
    +0.0003 (+0.03%)
     
  • Bitcoin GBP

    55,410.92
    -551.36 (-0.99%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

BUZZ-Shire: relief over FDA drug approval

** Shire (Xetra: S7E.DE - news) tops FTSE 100, up at its highest levels in more than 3 mths after the US FDA approves NPS Pharmaceuticals' drug Natpara - validating Shire's recent takeover of NPS

** Panmure Gordon hikes its TP for Shire to 5,500p vs 5,000p

** Broker - rated at five stars for recommendation accuracy on Shire, according to StarMine - calls deal a strong therapeutic & strategic fit & expects NPS nascent product portfolio to benefit from Shire's broader channel to market

** Analysts at Jefferies reckon the commercial opportunity for the drug should be significant

** Natpara designed to treat hypoparathyroidism, a condition in which the body's parathyroid gland does not secrete enough parathyroid hormone (RM (LSE: RM.L - news) : tricia.wright1.thomsonreuters.com@reuters.net)